Core Insights - HCW Biologics Inc. is participating in the 2025 GenScript Biotech Global Forum, focusing on challenges in cell and gene therapy (CGT) [1][5] - Dr. Hing C. Wong, the CEO, will discuss how proprietary molecules can reduce manufacturing costs and enhance clinical efficacy in CGT [3][4] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies aimed at extending healthspan by addressing chronic inflammation linked to various diseases [4] - The company has developed two drug discovery platforms, including the TOBI™ platform, which generates multi-functional fusion molecules for treating hematologic and solid tumors, viral infections, and age-related diseases [4] Event Details - The 2025 GenScript Biotech Global Forum will take place on January 15, 2025, in San Francisco, concurrently with the J.P. Morgan Healthcare Conference [2][6] - The panel discussion featuring Dr. Wong is scheduled from 4:05 PM to 5:00 PM PT [2] Industry Context - The gene and cell therapy sector is experiencing significant growth, driven by innovations in life sciences and substantial funding from global capital markets [5][6] - The forum aims to address recent advancements, commercialization challenges, and regulatory trends in the CGT field [6]
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025